Description

BridgeBio Pharma: Inside Its Attruby-Led Growth Strategy And The Next Wave Of High-Value Drug Launches!

BridgeBio Pharma reported a fourth quarter and full year 2025 marked by sustained commercial growth, multiple successful late-stage clinical readouts, and a strategic transition from a cash-consuming to a cash-generating biopharmaceutical company. The company’s flagship product, Attruby, demonstrated accelerating net product revenue growth with $146 million reported in Q4, contributing to total revenues of $502.1 million for the full year, significantly up from $221.9 million in 2024. Attruby’s growth was driven by expanding prescriber base, higher new patient starts, and strong patient adherence, positioning it as the only near-complete stabilizer on the ATTR cardiomyopathy market. The company highlighted Attruby’s differentiated profile including a rapid clinical benefit evident as early as one month, and clinical benefits in atrial fibrillation and variant populations.